Overexpression of miR-939-3p predicts poor prognosis and promotes progression in lung cancer

Abstract

BACKGROUND:

Lung cancer is the main cancer-related deaths worldwide. In this study, we explored the clinical prognostic significance and functional role of miR-939-3p in lung cancer.

METHODS:

We analyzed the expression of miR-939-3p in lung cancer tissues and cells by qRT-PCR. The prognostic significance of miR-939-3p was investigated using the Kaplan-Meier survival and Cox regression analyses. The CCK-8 assay was used to determine the role of miR-939-3p in cell proliferation. Transwell assays were used to determine the effects of miR-939-3p on cell migration and invasion abilities.

RESULTS:

The expression of miR-939-3p was upregulated in cancer tissues and cell lines compared with adjacent normal tissues and normal cells, respectively. The upregulated miR-939-3p was significantly associated with lymph node metastasis, TNM stage and poor prognosis of lung cancer patients. After the transfection of miR-939 mimic, overexpression of miR-939-3p promoted lung cancer cell proliferation, migration, and invasion.

CONCLUSION:

These findings suggested that miR-939-3p acts as an oncogene and promotes cell proliferation, migration, and invasion in lung cancer. miR-939-3p may be a potential independent prognostic biomarker in lung cancer.

Keywords

miR-939-3p lung cancer prognosis proliferation migration invasion

1. Introduction

Lung cancer is one of the most commonly diagnosed cancer with high incidence and high mortality rate worldwide [1]. Among lung cancer, approximately 85% is non-small cell lung cancer (NSCLC), which is associated with high mortality as the majority of patients have already reached an advanced stage at the time of initial diagnosis [2, 3, 4]. Although only about 15% of lung cancer cases are small cell lung cancer (SCLC), it has a higher degree of malignancy, faster progress and shorter over-survival compared to the NSCLC [5, 6]. Despite advances in standard treatments, such as surgery, radiotherapy, and chemotherapy, the 5-year overall survival rate of lung cancer patients is still relatively low. Thus, identifying novel molecules markers and new therapeutic strategies is still crucial.

MicroRNAs (miRNAs), a class of small noncoding (19–25 nucleotides) RNAs, serve as negative regulators of genes by binding to 3’-UTR of the target genes [7, 8]. Aberrant expression of miRNAs has been reported leading to altered biological function, such as cell growth, proliferation, differentiation, and migration [9, 10, 11]. Increasing evidence indicated that abnormal expression of miRNAs plays an important role in the pathological processes in various diseases, including cancers [12, 13, 14]. Identifying the role of miRNAs in diseases may provide a perspective therapeutics for the management of cancers or other diseases [14]. miR-939 has been reported dysregulated in several types of cancers, such as hepatocellular carcinoma [15], pancreatic cancer [16], and colon cancer [17]. miR-939-3p is found upregulated in non-small cell lung cancer and circulating miR-939 may have potential as a diagnostic biomarker for adenocarcinoma [18, 19]. However, the expression pattern of miR-939-3p in lung cancer tissues and functional role of miR-939-3p has not been thoroughly investigated in lung cancer.

In the present study, we examined the expression of miR-939-3p in lung cancer tissues and cell lines. We also analyzed the association between miR-939-3p expression and prognosis of lung cancer patients. In addition, the functional role of miR-939-3p in lung cancer was investigated.

2. Materials and methods

2.1 Patients and samples

A total of 118 pairs of lung cancer tissue specimens and adjacent normal tissue specimens were collected from lung cancer patients who underwent surgical resection between March 2011 and January 2013 at our hospital. All the patients did not receive any preoperative therapies, such as radiotherapy and chemotherapy. These tissue specimens were immediately put into liquid nitrogen and stored at $-$ 80 ${}^{\circ}$ C before use. The clinical characteristics, 5-year follow-up data, and histopathological diagnoses of patients were fully recorded. The written informed consent was signed by each participant. This study was approved by the Ethics Committee of Shandong Cancer Hospital Affiliated to Shandong University.

2.2 Cell culture and cell transfection

Human lung cancer cell lines (A549, H1299, HCC827, and H1650), as well as a non-cancerous MRC-5 cell line, were purchased from the Cell Source of the Academy of Sciences (Shanghai, China). All cell lines were cultured in DMEM medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% FBS (Invitrogen; Thermo Fisher Scientific, Inc.) and cultivated in a humidified incubator (Thermo Fisher Scientific, Inc.) at 37 ${}^{\circ}$ C with 5% CO ${}_{2}$ .

Before transfection, lung cancer cells were seeded into a 6-well plate at 30–50% confluence. miR-939-3p mimic, mimic negative control (mimic NC), miR-939-3p inhibitor or inhibitor NC was transfected into lung cancer cells for miR-939-3p overexpression or inhibition. The transfection of cells was performed using Lipofectamine 3000 Reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer’s protocol.

2.3 RNA extraction and qRT-PCR analysis

The total RNA was extracted from lung cancer tissues and cultured cells using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. Reverse transcription was performed using AMV first strand cDNA synthesis Kit (Sangon Biotech Co., Ltd., Shanghai, China). The expression levels of miR-939-3p were quantified using an SYBR Premix Ex Taq II kit (Takara, Dalian, China) in an ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) and normalized to U6. Relative expression of miR-939-3p was quantified with the 2 ${}^{-\Delta\Delta\text{Ct}}$ methods.

2.4 Cell proliferation assay

Cell proliferation assay was assessed by cell counting kit-8 (CCK-8, Dojindo, Kumamoto, Japan) following the manufacturer’s introduction. Lung cancer cells were incubated in 96-well plates (1 $\times$ 10 ${}^{3}$ cells/well) after 24 h of transfection at 37 ${}^{\circ}$ C with 5% CO ${}_{2}$ . Then CCK-8 reagent was added into cells and incubated for 1 h. The absorbance was measured using a microplate reader (Thermo Fisher Scientific) at 450 nm wavelength.

Figure 1.

Relative expression of miR-939-3p in lung cancer tissues and cell lines was measured by qRT-PCR. A. Expression of miR-939-3p is increased in lung cancer tissues compared with normal tissues. B. Relative expression of miR-939-3p is higher in four lung cancer cell lines compared with normal cell line MRC-5. ${}^{***}P<$ 0.001.

2.5 Cell migration and invasion assays

Cell migration and invasion assays were carried out using a 24-well Transwell system (Corning, NY, USA). For cell migration assay, transfected cells (1 $\times$ 10 ${}^{5}$ cells/well) were cultured into the upper chamber of transwell containing membrane (8 $\mu$ m pore size) in serum-free DMEM and 500 $\mu$ l DMEM containing 10% FBS was added into the lower chamber as a chemoattractant. After incubation for 24 h, the migrating cells were stained and counted using a microscope (Olympus, Tokyo, Japan). For invasion assay, the steps were the same as that of the migration assay except the top chamber was precoated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA).

2.6 Statistical analysis

Statistical analysis was performed using SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5.0 software (GraphPad Software, Inc., Chicago, USA). All values were presented as mean $\pm$ standard deviation (SD). All experiments were performed at least three times, and data analyses were performed using the $\chi^{2}$ test, Student’s $t$ -test or one-way ANOVA followed by Tukey’s post-hoc test. Survival analysis was established using the Kaplan-Meier method and Cox regression analysis. $P<$ 0.05 was defined as statistical significance.

3. Results

3.1 Expression of miR-939-3p is increased in lung cancer

The expression of miR-939-3p in 118 paired human lung cancer tissues and adjacent normal tissues was analyzed using qRT-PCR, which revealed that miR-939-3p expression was increased in lung cancer tissues compared with normal tissues ( $P<$ 0.001, Fig. 1A). Then we analyzed the expression of miR-939-3p in lung cancer cells. As shown in Fig. 1B, miR-939-3p expression exhibited relatively increased expression in lung cancer cells (A549, H1299, HCC827, and H1650), when compared with non-cancerous MRC-5 cell line ( $P<$ 0.001).

3.2 Correlations between lung cancer patients’ clinicopathological characteristics and miR-939-3p expression

The mean value of miR-939-3p level in lung cancer tissues was used as the cutoff point to divide lung cancer patients into low miR-939-3p expression group ( $n=$ 54) and high miR-939-3p expression group ( $n=$ 64). The association between patients’ clinicopathological characteristics and miR-939-3p expression was analyzed using the $\chi^{2}$ test. As shown in Table 1, the expression of miR-939-3p was significantly associated with lymph node metastasis ( $P=$ 0.009) and TNM stage ( $P=$ 0.007). However, statistical analysis showed no significant correlation between miR-939-3p expression and other characteristics, such as gender, age, tumor size, differentiation, and smoking history.

Table 1
Correlation between miR-939-3p expression levels and clinical features in lung cancer patients

Parameters	Cases no.	miR-939-3p		$P$
	( $n=$ 118)	expression
		Low	High
		( $n=$ 54)	( $n=$ 64)
Gender				0.676
Male	68	30	38
Female	50	24	26
Age				0.294
$<$ 60	63	26	37
$\geqslant$ 60	55	28	27
Tumor size				0.087
$<$ 5 cm	56	21	35
$\geqslant$ 5 cm	62	33	29
Smoking history				0.414
Yes	74	36	38
No	44	18	26
Differentiation				0.199
Well $+$ moderate	69	35	34
Poor	49	19	30
Lymph node metastasis				0.009 ${}^{*}$
Negative	61	35	26
Positive	57	19	38
TNM stage				0.007 ${}^{*}$
I–II	52	31	21
III–IV	66	23	43

${}^{*}P<$ 0.05.

Figure 2.

Kaplan-Meier method was used to evaluate the 5-year survival rate of patients with high and low expression of miR-939-3p.

3.3 The prognostic value of miR-939-3p in lung cancer

Considering miR-939-3p expression was significantly associated with lymph node metastases and TNM stage, we speculated that miR-939-3p expression might be related to the prognosis of lung cancer patients. To investigate the prognostic value of the miR-939-3p expression in lung cancer, Kaplan-Meier analysis was conducted to compare overall survival according to the miR-939-3p expression. As shown in Fig. 2, low miR-939-3p expression in tumor tissues showed a survival benefit in lung cancer patients ( $P=$ 0.017). Subsequently, we used a multivariate Cox regression analysis to investigate whether the expression of miR-939-3p is an independent prognostic factor for lung cancer. The results showed that the expression of miR-939-3p was an independent prognostic factor for lung cancer (HR $=$ 1.863, 95% CI $=$ 1.042–3.330, $P=$ 0.036, Table 2).

Table 2
Multivariate Cox analysis of clinical parameters in relation to overall survival

Characteristics	Multivariate analysis
	HR	95% CI	$P$
miR-939-3p	1.863	1.042–3.330	0.036 ${}^{*}$
Gender	0.931	0.561–1.543	0.781
Age	1.287	0.791–2.095	0.309
Tumor size	1.517	0.920–2.501	0.102
Smoking history	0.603	0.344–1.056	0.077
Differentiation	0.617	0.348–1.094	0.098
Lymph node metastasis	1.510	0.874–2.607	0.140
TNM stage	1.567	0.927–2.650	0.094

${}^{*}P<$ 0.05.

Figure 3.

Effects of miR-939-3p on cell proliferation in lung cancer using A549 and H1299 cells. A. The expression of miR-939-3p was measured in miR-939-3p mimic, mimic NC, miR-939-3p inhibitor, or inhibitor NC-transfected cells. B. Cell proliferation was determined using the CCK-8 assay. ${}^{*}P<$ 0.05, ${}^{***}P<$ 0.001.

Figure 4.

Effects of miR-939-3p on cell migration and invasion. A. Cell migration Transwell assay showed that overexpression of miR-939-3p promoted migration ability, while inhibition of miR-939-3p suppressed cell migratory ability, compared with untreated cells. B. Cell invasion Transwell assay indicated miR-939-3p promoted cell invasion. ${}^{**}P<$ 0.01, ${}^{***}P<$ 0.001.

3.4 miR-939-3p promoted cell proliferation, migration, and invasion

Because expression of miR-939-3p was found significantly upregulated in lung cancer tissues and cell lines, we investigated whether miR-939-3p acts as an oncogene role in cell proliferation, migration, and invasion of lung cancer. miR-939-3p mimic, miR-939-3p inhibitor, or their respective negative controls were transfected into A549 and H1299 cells, which have a relatively higher miR-939-3p expression. The qRT-PCR results showed that the expression of miR-939-3p in cells was significantly increased by miR-939-3p mimic, while decreased by the miR-939-3p inhibitor ( $P<$ 0.001, Fig. 3A). Results of CCK-8 assays showed that overexpression of miR-939 promoted cell proliferation, while inhibition of miR-939-3p suppressed cell proliferation ( $P<$ 0.05, Fig. 3B). In addition, Transwell assays results confirmed that upregulation of miR-939-3p markedly promoted the cell migration and invasion abilities, while downregulation of miR-939-3p decreased the migration and invasion abilities of lung cancer cells ( $P<$ 0.01, Fig. 4A and B).

4. Discussion

Lung cancer is the main cause of cancer-related mortality, with a relatively low overall survival worldwide [20]. Identifying novel biomarkers as possible prognostic predictors or therapeutic targets is still crucial. More and more studies indicated that the diverse roles of miRNAs in the development of various malignant neoplasm [13, 21, 22]. Some miRNAs can be a diagnostic or/and prognostic biomarker for cancers. For instance, Wang et al. suggested that the high expression of miR-411 was a diagnostic and prognostic biomarker for NSCLC patients [23]. Expression of miR-206 was unregulated and the expression of miR-145 was downregulated in breast cancer, both of them might serve as an important prognostic indicator of patients with breast cancer [24]. These above studies demonstrated that abnormal expression of miRNAs has potential diagnostic or prognostic value in cancers.

In the previous studies in lung cancer, Rani et al. applied global miRNAs expression profiling approaches in serum from lung adenocarcinoma patients and identified circulating miRNAs, including miR-939, having potential as diagnostic biomarkers for lung adenocarcinoma [19]. Based on miRNA and miRNA profiling, Yang et al. explored a novel therapeutic target of NSCLC, in which miR-939-3p is found upregulated in NSCLC tissues [18]. In another study by Ma et al. also constructed a global interaction network of miRNA-miRNA in NSCLC samples and found miR-1228 and miR-939 as essential nodes in network analysis [25]. These studies showed that miR-939 is potentially important for lung cancer. However, the role of miR-939-3p has not been thoroughly investigated in lung cancer.

In the present study, we investigated the expression of miR-939-3p in lung cancer tissues and cell lines. The results showed that the expression of miR-939-3p is increased in lung cancer tissues and cell lines, which is consistent with the results in the previous study [18, 19]. Overexpression of miR-939-3p is found to be closely associated with lymph node metastasis and advanced TNM stage, which suggested miR-939-3p expression may be involved in the development of lung cancer. According to the Kaplan-Meier analysis and Cox regression analysis results, overexpression of miR-939-3p is associated with shorter overall survival of patients and is an independent prognostic factor for lung cancer.

Numerous studies also identified that some miRNAs act as an oncogene or suppressor gene and involved in the progression of various cancers [26, 27, 28]. For instance, miR-338-3p functions as a suppressor gene in bladder cancer and inhibited the proliferation, metastasis, and EMT in bladder cancer through regulating ETS1 expression [27]. miR-1260b is found upregulated in NSCLC, promotes the cell migration and invasion, and can serve as a putative target for diagnosis and treatment of NSCLC [28]. Considering the expression of miR-939-3p is increased in lung cancer tissues and cell lines, we investigated whether miR-939-3p acts as an oncogene role in cell proliferation, migration, and invasion of lung cancer. The results showed that overexpression of miR-939-3p by miR-939-3p mimic promoted cell proliferation, migration, and invasion abilities, while inhibition of miR-939-3p suppresses those abilities. The development and progression of cancers is affected by a number of genes and signaling pathways [29, 30]. In gastric cancer, miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway [31]. In breast cancer, miR-939 was also found highly expressed and identified its extracellular protumorigenic role directly targeting VE-cadherin [32]. In ovarian cancer, miR-939 functions as a potential tumor promoter that promotes the proliferation of ovarian cancer cells by regulating the Wnt/ $\beta$ -catenin signaling pathway through directly repressing APC2 expression [33]. In a study by Xu et al. demonstrated that miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2 [34]. A previous study has indicated that Wnt signaling plays an important role in the development and metastasis of lung cancer [30]. We speculate miR-939-3p may also regulate the progression of lung cancer through the Wnt/ $\beta$ -catenin signaling pathway by directing inhibiting APC2 expression. In our current study, miR-939-3p is found associated with the prognosis of cancer patients and involved in the development and progression of lung cancer. In addition, the molecular mechanism of miR-939-3p will be studied in future investigation.

Taken together, miR-939-3p is upregulated in lung cancer tissues and cell lines and its overexpression promotes cell proliferation, migration, and invasion in vitro. What’s more, miR-939-3p may be an important prognostic biomarker and therapeutic target for the management of lung cancer.

Footnotes

Acknowledgments

This work was supported by Science and Technology Program of Binzhou Medical University Hospital (BY2015KJ31).

Conflict of interest

The authors declare that they have no conflicts of interest.

References

Mao

Yang

and Krasna

M.J.

, Epidemiology of lung cancer, Surg Oncol Clin N Am 25 (2016), 439–445.

Chen

W.Q.

Zuo

T.T.

Zheng

R.S.

Zeng

H.M.

Zhang

S.W.

and He

, Lung cancer incidence and mortality in China in 2013, Zhonghua Zhong Liu Za Zhi 39 (2017), 795–800.

Gotfrit

Jonker

Zhang

Goss

Nicholas

Laurie

and Wheatley-Price

, Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes, Cancer Treat Res Commun 19 (2019), 100130.

Morgensztern

S.H.

Gao

and Govindan

, Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey, J Thorac Oncol 5 (2010), 29–33.

Babadi

A.S.

Kiani

Mortaz

Taghavi

Khosravi

Marjani

Seifi

Emami

and Abedini

, Serum interleukin-27 level in different clinical stages of lung cancer, Open Access Maced J Med Sci 7 (2019), 45–49.

Oronsky

Reid

T.R.

Oronsky

and Carter

C.A.

, What’s new in SCLC? A review, Neoplasia 19 (2017), 842–847.

Fujiwara

and Yada

, miRNA-target prediction based on transcriptional regulation, BMC Genomics 14(Suppl 2) (2013), S3.

Pasquinelli

A.E.

, MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship, Nat Rev Genet 13 (2012), 271–282.

Zhang

Yin

Feng

and Hu

, MicroRNAs as big regulators of neural stem/progenitor cell proliferation, differentiation and migration: a potential treatment for stroke, Curr Pharm Des 23 (2017), 2252–2257.

10.

Kabekkodu

S.P.

Shukla

Varghese

V.K.

D.S.

Chakrabarty

and Satyamoorthy

, Clustered miRNAs and their role in biological functions and diseases, Biol Rev Camb Philos Soc 93 (2018), 1955–1986.

11.

Engin

A.B.

, MicroRNA and adipogenesis, Adv Exp Med Biol 960 (2017), 489–509.

12.

Tutar

, miRNA and cancer; computational and experimental approaches, Curr Pharm Biotechnol 15 (2014), 429.

13.

Alipoor

S.D.

Adcock

I.M.

Garssen

Mortaz

Varahram

Mirsaeidi

and Velayati

, The roles of miRNAs as potential biomarkers in lung diseases, Eur J Pharmacol 791 (2016), 395–404.

14.

Rupaimoole

and Slack

F.J.

, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, Nat Rev Drug Discov 16 (2017), 203–222.

15.

Fornari

Ferracin

Trere

Milazzo

Marinelli

Galassi

Venerandi

Pollutri

Patrizi

Borghi

Foschi

F.G.

Stefanini

G.F.

Negrini

Bolondi

and Gramantieri

, Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC, PLoS One 10 (2015), e0141448.

16.

Trehoux

Lahdaoui

Delpu

Renaud

Leteurtre

Torrisani

Jonckheere

and Van Seuningen

, Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells, Biochim Biophys Acta 1853 (2015), 2392–2403.

17.

Bobowicz

Skrzypski

Czapiewski

Marczyk

Maciejewska

Jankowski

Szulgo-Paczkowska

Zegarski

Pawlowski

Polanska

Biernat

Jaskiewicz

and Jassem

, Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer, Clin Exp Metastasis 33 (2016), 765–773.

18.

Yang

Sun

Liang

Xie

Huang

and Li

, Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer, Cancer Gene Ther 23 (2016), 90–97.

19.

Rani

Gately

Crown

O’Byrne

and O’Driscoll

, Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma, Cancer Biol Ther 14 (2013), 1104–1112.

20.

Hirsch

F.R.

Scagliotti

G.V.

Mulshine

J.L.

Kwon

Curran

W.J.

, Jr. Wu

Y.L.

and Paz-Ares

, Lung cancer: current therapies and new targeted treatments, Lancet 389 (2017), 299–311.

21.

Wang

R.H.

L.Y.

and Zhou

S.H.

, The role of gene sculptor microRNAs in human precancerous lesions, Onco Targets Ther 11 (2018), 5667–5675.

22.

Yang

Z.Q.

C.A.

and Cheng

Y.X.

, Prognostic value of microRNA-133a expression and its clinicopathologic significance in non-small cell lung cancer: a comprehensive study based on meta-analysis and the TCGA database, Oncol Res Treat 41 (2018), 762–768.

23.

Wang

S.Y.

Jiang

Y.S.

and Li

R.Z.

, Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer, Eur Rev Med Pharmacol Sci 21 (2017), 4092–4097.

24.

Quan

Huang

and Quan

, Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis, Oncol Lett 16 (2018), 6638–6642.

25.

Wang

and Xu

, miRNA-mRNA interaction network in non-small cell lung cancer, Interdiscip Sci 8 (2016), 209–219.

26.

Wang

J.R.

Liu

Zhou

and Huang

Y.X.

, MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer, Cancer Biomark 24 (2019), 159–172.

27.

Zhang

Yan

Zhang

S.N.

Zhang

H.Z.

Ruan

X.J.

Cao

and Gu

X.Z.

, MicroRNA-338-3p inhibits the progression of bladder cancer through regulating ETS1 expression, Eur Rev Med Pharmacol Sci 23 (2019), 1986–1995.

28.

Huang

Zhang

Niu

Chen

Ping

Min

Chen

Dai

and Dong

, MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK, Pathol Res Pract 214 (2018), 776–783.

29.

Zhang

Wang

Meng

Zhou

and Zhang

, The relationship between microRNAs and the STAT3-related signaling pathway in cancer, Tumour Biol 39 (2017), 1010428317719869.

30.

Yang

Chen

Shi

Cho

W.C.

and Liu

, Wnt signaling as potential therapeutic target in lung cancer, Expert Opin Ther Targets 20 (2016), 999–1015.

31.

Zhang

J.X.

Gao

Chen

Zheng

Z.S.

Yun

Weng

H.W.

Xie

and Ye

, Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway, Mol Cancer 16 (2017), 18.

32.

Di Modica

Regondi

Sandri

Iorio

M.V.

Zanetti

Tagliabue

Casalini

and Triulzi

, Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers, Cancer Lett 384 (2017), 94–100.

33.

Ying

Li-ya

Feng

Yin

and Ji-hong

, MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression, Biomed Pharmacother 71 (2015), 64–69.

34.

Zhang

Chen

and Xu

, miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2, Mol Cell Biochem 443 (2018), 151–157.

Overexpression of miR-939-3p predicts poor prognosis and promotes progression in lung cancer

Abstract

BACKGROUND:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Materials and methods

2.1 Patients and samples

2.2 Cell culture and cell transfection

2.3 RNA extraction and qRT-PCR analysis

2.4 Cell proliferation assay

2.6 Statistical analysis

3. Results

3.1 Expression of miR-939-3p is increased in lung cancer

3.2 Correlations between lung cancer patients’ clinicopathological characteristics and miR-939-3p expression

Table 1 Correlation between miR-939-3p expression levels and clinical features in lung cancer patients

Table 2 Multivariate Cox analysis of clinical parameters in relation to overall survival

4. Discussion

Footnotes

Acknowledgments

Conflict of interest

References

Table 1
Correlation between miR-939-3p expression levels and clinical features in lung cancer patients

Table 2
Multivariate Cox analysis of clinical parameters in relation to overall survival